<?xml version="1.0" encoding="ISO-8859-1"?><rss version="2.0" xmlns:creativeCommons="http://backend.userland.com/creativeCommonsRssModule" xmlns:dc="http://purl.org/dc/elements/1.1/">

<channel>
<title>Ardea Biosciences  Company Newsfeed</title>
<link>http://www.advfn.com/nasdaq/rss.asp?symbol=RDEA</link>
<description>Ardea Biosciences  Company Newsfeed</description>
<language>en</language>
<pubDate>Wed, 20 Jun 2012 03:18:04 EDT</pubDate>
<lastBuildDate>Wed, 20 Jun 2012 03:18:04 EDT</lastBuildDate>
  
  
 <item>
 <title>AstraZeneca Completes Acquisition of Ardea Biosciences</title>
 <link>http://www.advfn.com/nasdaq/StockNews.asp?stocknews=RDEA&amp;article=52824457&amp;headline=astrazeneca-completes-acquisition-of-ardea-biosciences</link>
 <guid>http://www.advfn.com/nasdaq/StockNews.asp?stocknews=RDEA&amp;article=52824457&amp;headline=astrazeneca-completes-acquisition-of-ardea-biosciences</guid>
 <description>&#60;div class='newsbody'&#62;&#60;p&#62; LONDON--Biopharmaceutical business AstraZeneca PLC (AZN.LN) said Wednesday that on June 19 it completed its acquisition of San Diego, California-based biotechnology company Ardea Biosciences, Inc. (RDEA). &#60;/p&#62;
&#60;p&#62; MAIN FACTS: &#60;/p&#62;
&#60;p&#62; -Upon completion of the merger, each outstanding...</description>
 <pubDate>Wed, 20 Jun 2012 03:18:04 EDT</pubDate>
 </item>

 <item>
 <title>Pharma M&amp;A Surge Spurred By Necessity And Opportunity</title>
 <link>http://www.advfn.com/nasdaq/StockNews.asp?stocknews=RDEA&amp;article=52187452&amp;headline=pharma-m-a-surge-spurred-by-necessity-and-opportunity</link>
 <guid>http://www.advfn.com/nasdaq/StockNews.asp?stocknews=RDEA&amp;article=52187452&amp;headline=pharma-m-a-surge-spurred-by-necessity-and-opportunity</guid>
 <description>&#60;div class='newsbody'&#62;&#60;p&#62; By Sten Stovall &#60;/p&#62;
&#60;p&#62; Of DOW JONES NEWSWIRES &#60;/p&#62;
&#60;p&#62; LONDON -(Dow Jones)- The sudden willingness of European drug companies to launch hostile takeover bids -- underscored by numerous bids this month -- underlines the depth of the sector's problems and its need to find new...</description>
 <pubDate>Fri, 27 Apr 2012 10:54:37 EDT</pubDate>
 </item>

 <item>
 <title>AstraZeneca Buys Ardea Biosciences For $1.26 Billion/$32 A Share</title>
 <link>http://www.advfn.com/nasdaq/StockNews.asp?stocknews=RDEA&amp;article=52100437&amp;headline=astrazeneca-buys-ardea-biosciences-for-1-26-billion-32-a-share</link>
 <guid>http://www.advfn.com/nasdaq/StockNews.asp?stocknews=RDEA&amp;article=52100437&amp;headline=astrazeneca-buys-ardea-biosciences-for-1-26-billion-32-a-share</guid>
 <description>&#60;div class='newsbody'&#62;&#60;p&#62; LONDON -(Dow Jones)- Global, innovation-driven biopharmaceutical business AstraZeneca PLC (AZN) said Monday it and Ardea Biosciences, Inc. (RDEA) have entered into a definitive merger agreement, for AstraZeneca to buy Ardea for $1.26 billion, including existing cash. &#60;/p&#62;
&#60;p&#62;...</description>
 <pubDate>Mon, 23 Apr 2012 02:46:13 EDT</pubDate>
 </item>

 <item>
 <title>Health Care Stocks Need Quite A Surge To Meet Latest Analyst...</title>
 <link>http://www.advfn.com/nasdaq/StockNews.asp?stocknews=RDEA&amp;article=41207393&amp;headline=health-care-stocks-need-quite-a-surge-to-meet-latest-analyst</link>
 <guid>http://www.advfn.com/nasdaq/StockNews.asp?stocknews=RDEA&amp;article=41207393&amp;headline=health-care-stocks-need-quite-a-surge-to-meet-latest-analyst</guid>
 <description>&#60;div class='newsbody'&#62;&#60;pre&#62; By Brendan Conway Of DOW JONES NEWSWIRES &#60;/pre&#62;
&#60;p&#62; NEW YORK -(Dow Jones)- Well before this week's Massachusetts electoral upset, Wall Street analysts were resuming their bullishness on health-care stocks. &#60;/p&#62;
&#60;p&#62; But to reach Wall Street analysts' newest price targets, some...</description>
 <pubDate>Thu, 21 Jan 2010 12:05:06 EST</pubDate>
 </item>

</channel>
</rss>